Suppr超能文献

微创经 antral 膜球囊提升术 - 多中心注册研究结果。

Minimally invasive antral membrane balloon elevation - results of a multicenter registry.

机构信息

Dental Clinic, Petah-Tikva, Israel.

出版信息

Clin Implant Dent Relat Res. 2009 Oct;11 Suppl 1:e83-91. doi: 10.1111/j.1708-8208.2009.00213.x. Epub 2009 Aug 3.

Abstract

BACKGROUND AND PURPOSE

Frequently, the posterior maxilla lacks sufficient bone mass to support dental implants. This multiphysician registry assessed the feasibility and safety of minimally invasive antral membrane balloon elevation (MIAMBE), followed by bone augmentation and implant fixation.

MATERIALS AND METHODS

One hundred twelve consecutive patients were referred for MIAMBE. Following pre-procedural assessment and informed consent, patients underwent alveolar crest exposure, and 3 mm osteotomy followed by MIAMBE. Platelet-rich fibrin and bone substitutes were injected under the antral membrane; implant placement and primary closure were executed at the same sitting. Implant loading was carried out 6 to 9 months later.

RESULTS

One hundred nine (97.3%) patients successfully concluded the initial procedure. Three patients had membrane tear requiring procedure abortion. One case of infection was documented at 4 weeks. Procedure time was 58 +/- 23 minutes. Incremental bone height consistently exceeded 10 mm, and implant survival of 95% was observed at 6 to 9 months.

CONCLUSION

MIAMBE can be applied to all patients in need of posterior maxilla bone augmentation with high procedural success, low complication rate, and satisfactory bone augmentation and implant survival. As it is minimally invasive and associated with minimal discomfort, MIAMBE should be an alternative to the currently employed methods of maxillary bone augmentation.

摘要

背景与目的

上颌后区常因骨量不足而无法植入种植体。本多医师注册研究评估了微创上颌窦底提升术(MIAMBE)联合骨增量和种植体固位的可行性和安全性。

材料与方法

112 例连续患者接受 MIAMBE 治疗。术前评估和知情同意后,患者行牙槽嵴暴露和 3mm 骨切开术,然后行 MIAMBE。在窦膜下注射富含血小板纤维蛋白和骨替代物;在同一阶段进行种植体植入和一期闭合。6-9 个月后进行种植体负荷。

结果

109 例(97.3%)患者成功完成初始手术。3 例患者发生膜撕裂,需终止手术。1 例患者在 4 周时发生感染。手术时间为 58±23 分钟。骨增量高度持续超过 10mm,6-9 个月时种植体存活率为 95%。

结论

MIAMBE 可应用于所有需要上颌后区骨增量的患者,具有较高的手术成功率、较低的并发症发生率,以及满意的骨增量和种植体存活率。由于 MIAMBE 具有微创性且患者不适感低,它应成为上颌骨增量的一种替代方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验